Companies in #Antibody-Drug Conjugates

ADC Therapeutics is a commercial-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for the treatment of hematologic cancers and solid tumors. Its lead product Zynlonta (loncastuximab tesirine) is the first CD19-targeted ADC approved for relapsed/refractory diffuse large B-cell lymphoma. The company is advancing a pipeline of next-generation ADCs targeting both hematologic malignancies and selected solid tumors.

Firefly Bio is a clinical-stage bioconjugate and antibody-drug conjugate (ADC) company leveraging chemistry pioneered by Nobel laureate Carolyn Bertozzi to develop next-generation ADCs targeting KRAS-mutant and other solid tumors. Its lead programs combine site-specific bioconjugation with tumor-selective payload chemistries designed to widen the therapeutic index versus first-generation ADC platforms.

Lonza Group AG is a Swiss multinational CDMO and contract manufacturing organization serving the pharmaceutical, biotech, and nutrition industries. In 2026 the company is expanding its antibody-drug conjugate (ADC) manufacturing capacity and broadening collaborations with US biopharma drug developers, with a focus on integrated biologics and small-molecule services.